Deferiprone market?

See the DrugPatentWatch profile for Deferiprone

What is Deferiprone used for?

Deferiprone is an oral iron-chelating agent used in the treatment of iron overload in patients with beta-thalassemia major [1]. It is designed to bind with iron and remove it from the body, reducing the risk of organ damage.

Clinical Significance

Deferiprone has been shown to be effective in reducing serum ferritin levels and improving hematological parameters in patients with beta-thalassemia major [2]. It is particularly useful for patients who cannot tolerate or respond to other iron chelators such as deferoxamine.

Patent and Exclusivity

According to DrugPatentWatch.com, the patent for Deferiprone is owned by Apopharma. The exclusive marketing rights for Deferiprone in the United States are held by Apopharma until 2025 [3].

Regulatory Status

Deferiprone has been approved by regulatory agencies worldwide, including the US FDA, the EMA, and Health Canada. It is available in several countries under the brand name Ferriprox.

Market Competition

While Deferiprone is a well-established treatment for iron overload, it faces competition from other iron chelators such as deferasirox (Exjade) and deferoxamine (Desferal). Additionally, biosimilars and generic versions of Deferiprone may enter the market after its patent expiry.

Patient Concerns and Side Effects

Deferiprone is generally well tolerated, but it can cause side effects such as gastrointestinal issues, fatigue, and changes in liver function. Patients should discuss the potential risks and benefits of Deferiprone with their healthcare provider.

Sources:

[1] - "Deferiprone" - Drugs@FDA database
[2] - "Deferiprone (Ferriprox) - Drug Information" - Medicines.org.uk
[3] - DrugPatentWatch.com

Sources:

1. Drugs@FDA database
2. Medicines.org.uk
3. DrugPatentWatch.com